Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlobalData Plc
  6. News
  7. Summary
    DATA   GB00B87ZTG26

GLOBALDATA PLC

(DATA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

GlobalData : Psilocybin has potential to become a breakthrough therapy for treatment-resistant depression if safety concerns are resolved, says GlobalData

11/18/2021 | 06:23am EST
18 Nov 2021
Psilocybin has potential to become a breakthrough therapy for treatment-resistant depression if safety concerns are resolved, says GlobalData
Posted in Pharma

Compass Pathways recently announced positive topline results for COMP360 (psilocybin), from the largest clinical trial to date, in conjunction with psychological support from specially trained therapists, for treatment-resistant depression (TRD). GlobalData, a leading data and analytics company, believes that this clinical trial demonstrates the potential of psilocybin to become a breakthrough therapy for TRD if safety concerns are resolved in later stage clinical trials.

Philippa Salter, Neurology Analyst at GlobalData, comments: "Approximately a third of patients with depression fail to respond to available antidepressant therapies and are referred to as having TRD. The positive efficacy results from Compass' trial indicate that psilocybin has the potential to address the significant unmet need for therapies targeting this group of patients. Furthermore, COMP360 was able to demonstrate significant effect only a day after administration. The drug demonstrated a rapid onset of action, which is of particular benefit for patients with severe depression, as other antidepressants normally take several weeks of treatment before an effect is seen."

Even before the results of this trial were announced, key opinion leaders interviewed by GlobalData said they were excited by the potential impact psychedelics, such as psilocybin, could have on the treatment of depression. In particular, they felt this novel way of treating the disorder could lead to shorter term treatment with lasting benefits, which would be hugely beneficial for patients who currently rely on maintenance treatments with a high pill burden.

Despite the positive results, the trial results raised important concerns surrounding the safety of psilocybin, with reports of suicidal behavior/ideation in a few of the trial participants.

Salter continues: "Suicide is particularly prevalent in patients with more severe depression such as those with TRD. Therefore, any therapy that has the potential to increase suicidal ideation/behavior, particularly in a vulnerable population, carries significant concern.

"However, it should be noted that since suicidal behavior is common in patients with TRD, further investigation will be required to determine whether the adverse effects seen were due to the psilocybin or the disease itself. The outcome of a larger Phase III trial will be vital in determining the safety of psilocybin and whether the benefits will outweigh the risks in such a hard-to-treat patient population."

Disclaimer

GlobalData plc published this content on 18 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 November 2021 11:22:03 UTC.


ę Publicnow 2021
All news about GLOBALDATA PLC
01/10GlobalData Flags 8% Like-For-Like Revenue Jump For 2021
MT
01/10GlobalData Provides Earnings Guidance for Fiscal 2021
CI
01/07GLOBALDATA : Solar PV and wind power market in the US will be driven by favorable governme..
PU
2021GLOBALDATA : Diagnosed incident cases of brain cancer to reach 147,000 by 2030 across 8MM,..
PU
2021GLOBALDATA : Influencers see investor sentiment to cool down for SPAC in 2022, finds Globa..
PU
2021GLOBALDATA : Global psoriasis market set to reach $27.5 billion by 2029 driven by the laun..
PU
20212022 PREDICTIONS : Further roll out of ‘explainable AI', a future less dominated by ..
PU
2021GLOBALDATA : Internet of Military Things has potential to transform warfare and serve as a..
PU
2021GLOBALDATA : Toyota fast-tracks EV ambitions with fresh investment, says GlobalData
PU
2021GlobalData Buys Automotive, Agribusiness Data Analytics Groups
MT
More news
Financials
Sales 2021 190 M 258 M 258 M
Net income 2021 26,3 M 35,8 M 35,8 M
Net Debt 2021 63,1 M 85,8 M 85,8 M
P/E ratio 2021 71,7x
Yield 2021 1,35%
Capitalization 1 669 M 2 267 M 2 270 M
EV / Sales 2021 9,14x
EV / Sales 2022 8,34x
Nbr of Employees 3 472
Free-Float 31,7%
Chart GLOBALDATA PLC
Duration : Period :
GlobalData Plc Technical Analysis Chart | DATA | GB00B87ZTG26 | MarketScreener
Technical analysis trends GLOBALDATA PLC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 14,15 GBX
Average target price 1 700,00 GBX
Spread / Average Target 11 914%
EPS Revisions
Managers and Directors
Michael Thomas Danson Chief Executive Officer & Director
Sally Kate Miranda Johnson Chief Financial Officer
Murray Legg Independent Non-Executive Chairman
Peter Martin Harkness Independent Non-Executive Director
Catherine Birkett Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GLOBALDATA PLC-0.70%2 280
S&P GLOBAL INC.-8.38%104 145
RELX PLC-6.37%59 236
THOMSON REUTERS CORPORATION-9.14%53 496
MSCI INC.-14.03%43 428
EQUIFAX INC.-14.79%30 439